Advertisement

The Three Asparaginases

Comparative Pharmacology and Optimal Use in Childhood Leukemia
  • Barbara L. Asselin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 457)

Abstract

Asparaginase (ASP) is a standard component of the antileukemia armamentarium. There are currently 3 preparations of asparaginase available: (1) E. coli (ASP, Elspar™); (2) the enzyme derived from Erwinia chrysanthemi (ERW, Erwinase™); (3) pegaspargase (PEG, Oncaspar™), the E. coli enzyme modified by covalent attachment of polyethylene glycol. This report describes the findings of 3 pharmacologic end points: ASP enzyme activity in patients’ sera, depletion of asparagine and the development of anti-ASP antibodies. Pharmacokinetics and pharmacodynamic studies in a group of naive children with newly diagnosed ALL demonstrate a significant difference in apparent half-life (1.24 days E. coli vs. 0.65 ERW vs. 5.73 PEG; p < 0.001) and days of asparagine depletion (14–23 E. coli vs. 7–15 ERW vs. 26–34 PEG; p < 0.01) for the 3 different preparations. Data from Pediatric Oncology Group (POG) Protocol #8866 show that high antibody levels correlated with rapid ASP clearance and a significantly lower response rate (NR = 26% vs. CR + PR+64%). The pharmacologie characteristics of ASP in terms of clearance of enzyme activity and ability to deplete serum asparagine was dependent upon the nature of the enzyme and are significantly altered in patients who develop anti-ASP antibodies regardless of their clinical status. In addition, these data demonstrate that ASP pharmacokinetics are directly related to its anti-leukemic effect. In order to maximize the therapeutic benefits of ASP, the optimal dose and schedule of treatment should be determined based on pharmacologic testing rather than by clinical criteria alone. Future studies will focus on the role of “silent hypersensitivity” as a mechanism of resistance to ASP and strategies to maximize the therapeutic efficacy of ASP as part of ALL therapy.

Keywords

asparaginase acute lymphoblastic leukemia childhood leukemia pharmacology hypersensitivity drug resistance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Broome JD. “Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects” Nature 1961, 191:1144–1115.CrossRefGoogle Scholar
  2. 2.
    Killander D, Dohlwitz A, Engstedt L, Franzen S, Gahrton G, Gullbring B, Holm G, Holmgren A, Hoglund S, Killander A, Lockner D, Mellstedt H, Moe PJ, Palmblad J, Reizenstein P, Skarberg KD, Swedberg B, Uden AM, Wadman B, Wide L, Ahstrom L. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976, 37:220–228.PubMedCrossRefGoogle Scholar
  3. 3.
    Land VJ, Shuster JJ, Pullen J, Harris M, Krance RA, Castleberry R, Akabutu J, Barbosa JL and Rosen D. Unexpectedly high incidence of allergic reactions with high dose weekly asparaginase consolidation therapy in children with newly diagnosed non-T, non-B acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Proc Am Soc Clin Oncol 1989, 8: 215, A834.Google Scholar
  4. 4.
    Cheung NKV, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Am J Pediatr Hematol/Oncol 1986, 8(2):99–104.Google Scholar
  5. 5.
    Fabry U, Korholz D, Jurgens H, Gobel U, and Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children — evidence of a complement-mediated mechanism. Pediatr Res 1985, 19:400–408.PubMedCrossRefGoogle Scholar
  6. 6.
    Kurtzberg J, Asselin B, Pollack B, Bernstein M, Buchanan G, and the Pediatric Oncology Group. PEG L-asparaginase vs native E. coli asparaginase for reinduction of relapsed acute lymphoblastic leukemia: POG #8866 phase II trial. Proc ASOC 1993, 12: p325, 1079A.Google Scholar
  7. 7.
    Kurtzberg J, Asselin B, Poplack D, Grebanier A, Chen R, Franklin A, Scudiery D and Fisherman J. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proc AACR 1993, 34: p304, 1807A.Google Scholar
  8. 8.
    Kurtzberg J, Asselin B, Pollack B, Ettinger L, Ravindranath Y, Faucey J and Fisherman J. PEG-L-asparaginase pharmacology in pediatric patients with acute lymphoblastic leukemia. Proc ASCO 1994, 13: p144, 370A.Google Scholar
  9. 9.
    Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE and Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993, 11(9): 1780–1786.PubMedGoogle Scholar
  10. 10.
    Asselin BL, Lorenson My, Whitin JC, Coppola DJ, Kende AS, Blakley RL and Cohen HJ. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 1991, 51:6568–6573.PubMedGoogle Scholar
  11. 11.
    Abshire T, Pollock B, Billett A, Bradley P, and Buchanan G. Weekly polyethylene glycol conjugated L-asparaginase produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study 9310. Proc ASCO 1995, 14: p344, 1038A.Google Scholar
  12. 12.
    Jones B, Holland JF, Glidewell O, Jacquillat C, Weil M, Pochedly C, Sinks L, Chevalier L, Maurer HM, Koch Kjell, Falkson G, Patterson R, Seligman B, Sartorious J, Kung F, Haurani F, Stuart M, Burgert EO, Ruymann F, Sawitsky A, Forman E, Pluess H, Truman J, Hakami N. Optimal use of L-asparaginase (NSC — 109229) in acute lymphocytic leukemia. Med Pediatr Oncol 1977, 3:387–400.PubMedCrossRefGoogle Scholar
  13. 13.
    Ertel IJ, Nesbit ME, Hammond D, Weiner J, and Sather H. Effective dose of L-asparaginase for inductio of remission in previously treated children with acute lymphoblastic leukemia: A report for the Children’s Cancer Study Group. Cancer Res 1979, 39:3893–3896.PubMedGoogle Scholar
  14. 14.
    Sallan SE, Hitchcok-Bryan S, Gelber R, Cassady JR, Frei III E, and Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983, 43:5601–5607.PubMedGoogle Scholar
  15. 15.
    Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, and Sallan SE. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986, 315:657–663.PubMedCrossRefGoogle Scholar
  16. 16.
    Boos J, Werber G, Verspolh E, Nowak-Goth U, Jurgens H. Asparagine levels in children on E. coli and Erwinia — asparaginase therapy. Haematol Blood Transfusion 37: Acute Leukemias V — Hiddemann et al (eds) Springer-Verlag Berlin Heidelberg, 1996, p67–69.Google Scholar
  17. 17.
    DiBenedetto SP, DiCataldo A, Ragusa R, Meli C and Lo Nigrio L. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol 1995, 13:339–344.PubMedGoogle Scholar
  18. 18.
    Ohnuma T, Holland JF, Freeman et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970, 30:2297–2305.PubMedGoogle Scholar
  19. 19.
    Capizzi RL, Bertino JR, Skeel RT, et al. Clinical, biochemical, pharmacological and immunological studies. Ann Intern Med 1971, 74:893–901.PubMedCrossRefGoogle Scholar
  20. 20.
    Boos J, Nowak-Gottl U, Jurgens H, Fleischhack G, Bode U. Loss of activity of Erwinia asparaginase on repeat applications (Letter). J Clin Oncol 1995, 13:2474–2475.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Barbara L. Asselin
    • 1
    • 2
  1. 1.The Children’s Hospital at Strong, University of Rochester School of Medicine and DentistryRochesterUSA
  2. 2.Cancer Center at the University of Rochester Medical CenterRochesterUSA

Personalised recommendations